Page 80 - Registration Document News Today

Conference call and webcast in English on February 16, 2023 at 8:30am EST 02:30pm CET and in French on the same day at 12pm EST 6pm CET Strategic combination would build on complementary expertise

Three-year data - with a median follow-up of 44 months - from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib regardless

Sibnayal® will now be available in four of the five major European markets Significant expansion of commercial opportunities for Sibnayal® (potassium citrate/ potassium bicarbonate) Regulatory

Investegate announcements from Ipsen Pharma, Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Clichy, France - February 14, 2023 BIC FOURTH QUARTER & FULL YEAR 2022 RESULTS Company's Horizon Plan Accelerates Global Growth In All Divisions,Delivers Another Outstanding Net Sales Performance

RESULTS AT 31 DECEMBER 2022 Press releaseParis, 8 February 2023 EXCELLENT PERFORMANCE ACROSS BUSINESS LINES Record revenues up by +9.3%(1)...

Investegate announcements from TotalEnergies SE, TotalEnergies: Fourth Quarter and Full-year 2022 Results

DJ Lepermislibre: Lepermislibre announces the success of its IPO on the Euronext Growth® market in Paris Lepermislibre Lepermislibre: Lepermislibre announces the success of its IPO on the Euronext

TotalEnergies leverages global portfolio to post adjusted net income of $7.6 billion in the fourth quarter 2022 and IFRS full-year net income of $20.5 billion TotalEnergies confirms 2023 pay-out

DJ Lepermislibre: Lepermislibre announces the success of its IPO on the Euronext Growth® market in Paris Lepermislibre Lepermislibre: Lepermislibre announces the success of its IPO on the Euronext